辅助内分泌治疗中卵巢功能抑制不足与充分的比较:两项前瞻性研究的探索性分析
该探索性分析基于PREFER和GIM 23-POSTER两项意大利多中心前瞻性观察研究,纳入 coordinating center 的488例绝经前乳腺癌患者,中位随访44.4个月。343例接受辅助内分泌治疗者中,28例(8.2%)为OFS不足,315例为充分抑制;仅联用AI与OFS不足显著相关(HR 12.83,95%CI 3.01-54.65,p=0.001),OFS不足比例从第1年5.1%升至5年内10.5%。
要点
- 约10%接受GnRHa辅助内分泌治疗的绝经前乳腺癌患者未达到完全OFS。
- 联用AI是OFS不足的唯一显著相关因素(HR 12.83,95%CI 3.01-54.65)。
- OFS不足比例从治疗第1年5.1%升至5年内10.5%,需长期监测。
核心结论
- 约10%以GnRHa行辅助内分泌治疗的绝经前乳腺癌患者未达到完全OFS,联用AI是OFS不足的唯一显著相关因素。
研究设计与样本
- PREFER(NCT02895165)和GIM 23-POSTER(NCT05730647)为意大利多中心前瞻性观察研究,本分析仅纳入协调中心入组患者,共488例,中位随访44.4个月(IQR 20.6-84.0)。
- 343例接受辅助内分泌治疗的患者按OFS状态分为OFS不足组(雌二醇>25.1 ng/L或月经恢复)28例和OFS充分组315例。
主要发现
- OFS不足组和充分组分别有55.9%和92.9%的患者联用AI。
- 年龄、BMI、基线FSH和雌二醇水平及既往化疗(含或不含同期GnRHa)与OFS不足无显著关联。
- 联用AI是OFS不足的唯一显著相关因素(HR 12.83,95%CI 3.01-54.65;p=0.001)。
- OFS不足比例在内分泌治疗第1年为5.1%(95%CI 3.2-8.2),5年内升至10.5%(95%CI 7.1-15.4)。
关键数值与推荐
- OFS不足定义为化学发光免疫分析法测得雌二醇>25.1 ng/L或月经恢复。
临床怎么用
- 对接受GnRHa辅助内分泌治疗的绝经前乳腺癌患者,尤其联用AI者,应监测雌二醇水平和月经状态以评估OFS是否充分。
- OFS不足比例随治疗时间延长而升高,提示需在5年治疗期间持续关注OFS充分性。
局限性
- 本分析仅纳入协调中心入组患者,非全部研究人群。
- 为探索性分析,样本量有限,OFS不足组仅28例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ovarian function suppression (OFS) combined with tamoxifen or aromatase inhibitor (AI) are standard treatment options for young women with hormone receptor-positive breast cancer. Suboptimal OFS may reduce the efficacy of the endocrine treatment (ET). This study evaluated factors associated with suboptimal OFS induced by gonadotropin-releasing hormone agonist (GnRHa). METHODS: PREFER (NCT02895165) and GIM 23-POSTER (NCT05730647) are multicentric Italian prospective, observational studies enrolling premenopausal women undergoing (neo)adjuvant chemotherapy and/or ET. The present analysis includes only patients enrolled at the coordinating center. Patients receiving ET with OFS were classified into suboptimal (estradiol >25.1 ng/L measured by chemiluminescent immunoassay or resumed menstruation) or adequate OFS. RESULTS: As of June 2024, 488 patients were enrolled (median follow-up: 44.4 months, IQR 20.6-84.0). Of 343 patients receiving adjuvant ET, 315 were in the adequately suppressed group and 28 in the suboptimal suppression group (of whom 55.9 % and 92.9 %, respectively, were receiving an AI). Clinical characteristics (age, BMI, baseline FSH, and estradiol levels) and previous chemotherapy (with or without concurrent GnRHa) showed no association with suboptimal OFS. Concurrent treatment with AI was the only factor significantly associated with suboptimal OFS (HR 12.83, 95 % CI 3.01-54.65; p = 0.001). The proportion of patients with suboptimal suppression was 5.1 % (95 % CI 3.2-8.2) in the first year of ET, rising to 10.5 % (95 % CI 7.1-15.4) within five years. CONCLUSIONS: Approximately 10 % of premenopausal women receiving GnRHa as part of adjuvant ET did not achieve complete OFS. Use of AI was the only factor linked to suboptimal OFS.
引用
- Nardin S, Bruzzone M, Arecco L, et al. Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies. Eur J Cancer. 2026. PMID: 41650785. doi:10.1016/j.ejca.2026.116266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。